Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 72R4G | IM / RA |
Rash; Itching; This non-serious case was reported by a other health professional via call center representative and described the occurrence of rash in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number 72R4G, expiry date 05-JUN-2027) for prophylaxis. On 11-OCT-2025, the patient received the 1st dose of Shingrix (intramuscular, right deltoid). On 11-OCT-2025, less than a day after receiving Shingrix, the patient experienced rash (Verbatim: Rash) and pruritus (Verbatim: Itching). The outcome of the rash and pruritus were not resolved. It was unknown if the reporter considered the rash and pruritus to be related to Shingrix. It was unknown if the company considered the rash and pruritus to be related to Shingrix. Additional Information: GSK receipt date: 13-OCT-2025 Patient developed a rash at the injection site down to her elbow and a rash on feet and hands on Saturday evening. The rash was still present, not better or worse. The patient tried topical ointments (nothing systemic) with no relief. The patient was presenting today with itching (out of hand), with no relief.